Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Bovée JV[au]:

Search results

Items: 1 to 50 of 221

1.

A subset of epithelioid and spindle cell rhabdomyosarcomas is associated with TFCP2 fusions and common ALK upregulation.

Le Loarer F, Cleven AHG, Bouvier C, Castex MP, Romagosa C, Moreau A, Salas S, Bonhomme B, Gomez-Brouchet A, Laurent C, Le Guellec S, Audard V, Giraud A, Ramos-Oliver I, Cleton-Jansen AM, Savci-Heijink DC, Kroon HM, Baud J, Pissaloux D, Pierron G, Sherwood A, Coindre JM, Bovée JVMG, Larousserie F, Tirode F.

Mod Pathol. 2019 Aug 5. doi: 10.1038/s41379-019-0323-8. [Epub ahead of print]

PMID:
31383960
2.

Conventional chondrosarcoma with focal clear cell change: a clinicopathological and molecular analysis.

Lam SW, van Langevelde K, Suurmeijer AJH, Cleven AHG, Bovée JVMG.

Histopathology. 2019 Jul 11. doi: 10.1111/his.13952. [Epub ahead of print]

PMID:
31297850
3.

NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2-3, randomised, controlled trial.

Bonvalot S, Rutkowski PL, Thariat J, Carrère S, Ducassou A, Sunyach MP, Agoston P, Hong A, Mervoyer A, Rastrelli M, Moreno V, Li RK, Tiangco B, Herraez AC, Gronchi A, Mangel L, Sy-Ortin T, Hohenberger P, de Baère T, Le Cesne A, Helfre S, Saada-Bouzid E, Borkowska A, Anghel R, Co A, Gebhart M, Kantor G, Montero A, Loong HH, Vergés R, Lapeire L, Dema S, Kacso G, Austen L, Moureau-Zabotto L, Servois V, Wardelmann E, Terrier P, Lazar AJ, Bovée JVMG, Le Péchoux C, Papai Z.

Lancet Oncol. 2019 Aug;20(8):1148-1159. doi: 10.1016/S1470-2045(19)30326-2. Epub 2019 Jul 8. Erratum in: Lancet Oncol. 2019 Sep;20(9):e468.

PMID:
31296491
4.

Radiotherapy resistance in chondrosarcoma cells; a possible correlation with alterations in cell cycle related genes.

de Jong Y, Ingola M, Briaire-de Bruijn IH, Kruisselbrink AB, Venneker S, Palubeckaite I, Heijs BPAM, Cleton-Jansen AM, Haas RLM, Bovée JVMG.

Clin Sarcoma Res. 2019 May 28;9:9. doi: 10.1186/s13569-019-0119-0. eCollection 2019.

5.

Non-ossifying fibroma: A RAS-MAPK driven benign bone neoplasm.

Bovée JV, Hogendoorn PC.

J Pathol. 2019 Jun;248(2):127-130. doi: 10.1002/path.5259. Epub 2019 Mar 20.

6.

Machine learning analysis of gene expression data reveals novel diagnostic and prognostic biomarkers and identifies therapeutic targets for soft tissue sarcomas.

van IJzendoorn DGP, Szuhai K, Briaire-de Bruijn IH, Kostine M, Kuijjer ML, Bovée JVMG.

PLoS Comput Biol. 2019 Feb 20;15(2):e1006826. doi: 10.1371/journal.pcbi.1006826. eCollection 2019 Feb.

7.

Exploration of the chondrosarcoma metabolome; the mTOR pathway as an important pro-survival pathway.

Addie RD, de Jong Y, Alberti G, Kruisselbrink AB, Que I, Baelde H, Bovée JVMG.

J Bone Oncol. 2019 Jan 29;15:100222. doi: 10.1016/j.jbo.2019.100222. eCollection 2019 Apr.

8.

Prevalence and Clinical Features of Mazabraud Syndrome: A Multicenter European Study.

Majoor BCJ, van de Sande MAJ, Appelman-Dijkstra NM, Leithner A, Jutte PC, Vélez R, Perlaky T, Staals EL, Bovée JVMG, Hamdy NAT, Dijkstra SPD.

J Bone Joint Surg Am. 2019 Jan 16;101(2):160-168. doi: 10.2106/JBJS.18.00062.

PMID:
30653046
9.

Increased WISP1 expression in human osteoarthritic articular cartilage is epigenetically regulated and decreases cartilage matrix production.

van den Bosch MHJ, Ramos YFM, den Hollander W, Bomer N, Nelissen RGHH, Bovée JVMG, van den Berg WB, van Lent PLEM, Blom AB, van der Kraan PM, Meulenbelt I.

Rheumatology (Oxford). 2019 Jun 1;58(6):1065-1074. doi: 10.1093/rheumatology/key426.

PMID:
30649473
10.

Soft tissue aneurysmal bone cyst: six new cases with imaging details, molecular pathology, and review of the literature.

Song W, Suurmeijer AJH, Bollen SM, Cleton-Jansen AM, Bovée JVMG, Kroon HM.

Skeletal Radiol. 2019 Jul;48(7):1059-1067. doi: 10.1007/s00256-018-3135-x. Epub 2019 Jan 2. Review.

PMID:
30603771
11.

Molecular Pathology of Bone Tumors.

Lam SW, van IJzendoorn DGP, Cleton-Jansen AM, Szuhai K, Bovée JVMG.

J Mol Diagn. 2019 Mar;21(2):171-182. doi: 10.1016/j.jmoldx.2018.11.002. Epub 2018 Dec 18. Review.

PMID:
30572118
12.

PRAME and HLA Class I expression patterns make synovial sarcoma a suitable target for PRAME specific T-cell receptor gene therapy.

Luk SJ, van der Steen DM, Hagedoorn RS, Jordanova ES, Schilham MW, Bovée JV, Cleven AH, Falkenburg JF, Szuhai K, Heemskerk MH.

Oncoimmunology. 2018 Sep 11;7(12):e1507600. doi: 10.1080/2162402X.2018.1507600. eCollection 2018.

13.

Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Casali PG, Bielack S, Abecassis N, Aro HT, Bauer S, Biagini R, Bonvalot S, Boukovinas I, Bovee JVMG, Brennan B, Brodowicz T, Broto JM, Brugières L, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Dhooge C, Eriksson M, Fagioli F, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gaspar N, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Haas RL, Hassan B, Hecker-Nolting S, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kager L, Kasper B, Kopeckova K, Krákorová DA, Ladenstein R, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Morland B, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Strauss SJ, Sundby Hall K, Unk M, Van Coevorden F, van der Graaf WTA, Whelan J, Wardelmann E, Zaikova O, Blay JY; ESMO Guidelines Committee, PaedCan and ERN EURACAN.

Ann Oncol. 2018 Oct 1;29(Suppl 4):iv79-iv95. doi: 10.1093/annonc/mdy310. No abstract available.

14.

Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Casali PG, Abecassis N, Aro HT, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Brodowicz T, Broto JM, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Haas RL, Hassan B, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kasper B, Kopeckova K, Krákorová DA, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Sundby Hall K, Unk M, Van Coevorden F, van der Graaf WTA, Whelan J, Wardelmann E, Zaikova O, Blay JY; ESMO Guidelines Committee and EURACAN.

Ann Oncol. 2018 Oct 1;29(Suppl 4):iv268-iv269. doi: 10.1093/annonc/mdy321. No abstract available.

15.

Bcl-xl as the most promising Bcl-2 family member in targeted treatment of chondrosarcoma.

de Jong Y, Monderer D, Brandinelli E, Monchanin M, van den Akker BE, van Oosterwijk JG, Blay JY, Dutour A, Bovée JVMG.

Oncogenesis. 2018 Sep 21;7(9):74. doi: 10.1038/s41389-018-0084-0.

16.

Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Casali PG, Abecassis N, Aro HT, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Brodowicz T, Broto JM, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Haas RL, Hassan B, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kasper B, Kopeckova K, Krákorová DA, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Sundby Hall K, Unk M, Van Coevorden F, van der Graaf WTA, Whelan J, Wardelmann E, Zaikova O, Blay JY; ESMO Guidelines Committee and EURACAN.

Ann Oncol. 2018 Oct 1;29(Suppl 4):iv267. doi: 10.1093/annonc/mdy320. No abstract available.

17.

Jason L. Hornick: Practical soft tissue pathology: a diagnostic approach, 2nd edition.

Bovée JVMG.

Virchows Arch. 2018 Dec;473(6):785-786. doi: 10.1007/s00428-018-2440-z. Epub 2018 Aug 29. No abstract available.

PMID:
30159597
18.

Low-grade central fibroblastic osteosarcoma may be differentiated from its mimicker desmoplastic fibroma by genetic analysis.

Song W, van den Berg E, Kwee TC, Jutte PC, Cleton-Jansen AM, Bovée JVMG, Suurmeijer AJ.

Clin Sarcoma Res. 2018 Aug 23;8:16. doi: 10.1186/s13569-018-0104-z. eCollection 2018.

19.

Does CSF1 overexpression or rearrangement influence biological behaviour in tenosynovial giant cell tumours of the knee?

Mastboom MJL, Hoek DM, Bovée JVMG, van de Sande MAJ, Szuhai K.

Histopathology. 2019 Jan;74(2):332-340. doi: 10.1111/his.13744. Epub 2018 Nov 11.

PMID:
30152874
20.

Molecular Analysis of Gene Fusions in Bone and Soft Tissue Tumors by Anchored Multiplex PCR-Based Targeted Next-Generation Sequencing.

Lam SW, Cleton-Jansen AM, Cleven AHG, Ruano D, van Wezel T, Szuhai K, Bovée JVMG.

J Mol Diagn. 2018 Sep;20(5):653-663. doi: 10.1016/j.jmoldx.2018.05.007. Epub 2018 Aug 20.

PMID:
30139549
21.

Outcome of First-Line Systemic Treatment for Unresectable Conventional, Dedifferentiated, Mesenchymal, and Clear Cell Chondrosarcoma.

van Maldegem A, Conley AP, Rutkowski P, Patel SR, Lugowska I, Desar IME, Bovée JVMG, Gelderblom H.

Oncologist. 2019 Jan;24(1):110-116. doi: 10.1634/theoncologist.2017-0574. Epub 2018 Aug 6.

PMID:
30082492
22.

Outcome of Nonsurgical Management of Extra-Abdominal, Trunk, and Abdominal Wall Desmoid-Type Fibromatosis: A Population-Based Study in the Netherlands.

van Broekhoven DLM, Verschoor AJ, van Dalen T, Grünhagen DJ, den Bakker MA, Gelderblom H, Bovee JVMG, Haas RLM, Bonenkamp HJ, van Coevorden F, Ten Oever D, van der Graaf WTA, Flucke UE, Pras E, Reyners AKL, Westermann AM, Oldenburger F, Verhoef C, Steeghs N.

Sarcoma. 2018 Jun 21;2018:5982575. doi: 10.1155/2018/5982575. eCollection 2018.

23.

Incidence and demographics of giant cell tumor of bone in The Netherlands: First nationwide Pathology Registry Study.

Verschoor AJ, Bovée JVMG, Mastboom MJL, Sander Dijkstra PD, Van De Sande MAJ, Gelderblom H.

Acta Orthop. 2018 Oct;89(5):570-574. doi: 10.1080/17453674.2018.1490987. Epub 2018 Jul 10.

24.

Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Casali PG, Abecassis N, Aro HT, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Brodowicz T, Broto JM, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Haas RL, Hassan B, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kasper B, Kopeckova K, Krákorová DA, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Sundby Hall K, Unk M, Van Coevorden F, van der Graaf WTA, Whelan J, Wardelmann E, Zaikova O, Blay JY; ESMO Guidelines Committee and EURACAN.

Ann Oncol. 2018 Oct 1;29(Suppl 4):iv68-iv78. doi: 10.1093/annonc/mdy095. No abstract available. Erratum in: Ann Oncol. 2018 Oct 1;29(Suppl 4):iv267.

PMID:
29846513
25.

Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Casali PG, Abecassis N, Aro HT, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Brodowicz T, Broto JM, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Haas RL, Hassan B, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kasper B, Kopeckova K, Krákorová DA, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Sundby Hall K, Unk M, Van Coevorden F, van der Graaf WTA, Whelan J, Wardelmann E, Zaikova O, Blay JY; ESMO Guidelines Committee and EURACAN.

Ann Oncol. 2018 Oct 1;29(Suppl 4):iv51-iv67. doi: 10.1093/annonc/mdy096. No abstract available. Erratum in: Ann Oncol. 2018 Oct 1;29(Suppl 4):iv268-iv269.

PMID:
29846498
26.

Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation.

Peterse EFP, Niessen B, Addie RD, de Jong Y, Cleven AHG, Kruisselbrink AB, van den Akker BEWM, Molenaar RJ, Cleton-Jansen AM, Bovée JVMG.

Br J Cancer. 2018 Apr;118(8):1074-1083. doi: 10.1038/s41416-018-0050-9. Epub 2018 Mar 26.

27.

Telatinib Is an Effective Targeted Therapy for Pseudomyogenic Hemangioendothelioma.

van IJzendoorn DGP, Sleijfer S, Gelderblom H, Eskens FALM, van Leenders GJLH, Szuhai K, Bovée JVMG.

Clin Cancer Res. 2018 Jun 1;24(11):2678-2687. doi: 10.1158/1078-0432.CCR-17-3512. Epub 2018 Mar 6.

28.

A remarkable response to pazopanib, despite recurrent liver toxicity, in a patient with a high grade endometrial stromal sarcoma, a case report.

Verschoor AJ, Warmerdam FARM, Bosse T, Bovée JVMG, Gelderblom H.

BMC Cancer. 2018 Jan 22;18(1):92. doi: 10.1186/s12885-018-3999-0.

29.

The role of metabolic enzymes in mesenchymal tumors and tumor syndromes: genetics, pathology, and molecular mechanisms.

Schaefer IM, Hornick JL, Bovée JVMG.

Lab Invest. 2018 Apr;98(4):414-426. doi: 10.1038/s41374-017-0003-6. Epub 2018 Jan 16. Review.

30.

The incidence, mutational status, risk classification and referral pattern of gastro-intestinal stromal tumours in the Netherlands: a nationwide pathology registry (PALGA) study.

Verschoor AJ, Bovée JVMG, Overbeek LIH; PALGA group, Hogendoorn PCW, Gelderblom H.

Virchows Arch. 2018 Feb;472(2):221-229. doi: 10.1007/s00428-017-2285-x. Epub 2018 Jan 8.

31.

Increased infiltration of M2-macrophages, T-cells and PD-L1 expression in high grade leiomyosarcomas supports immunotherapeutic strategies.

Kostine M, Briaire-de Bruijn IH, Cleven AHG, Vervat C, Corver WE, Schilham MW, Van Beelen E, van Boven H, Haas RL, Italiano A, Cleton-Jansen AM, Bovée JVMG.

Oncoimmunology. 2017 Oct 26;7(2):e1386828. doi: 10.1080/2162402X.2017.1386828. eCollection 2018.

32.

Successful disinfection of femoral head bone graft using high hydrostatic pressure.

van de Sande MAJ, Bovée JVMG, van Domselaar M, van Wijk MJ, Sanders I, Kuijper E.

Cell Tissue Bank. 2018 Sep;19(3):333-340. doi: 10.1007/s10561-017-9678-6. Epub 2017 Dec 20.

33.

Immune checkpoint inhibitors in sarcomas: in quest of predictive biomarkers.

Veenstra R, Kostine M, Cleton-Jansen AM, de Miranda NF, Bovée JV.

Lab Invest. 2018 Jan;98(1):41-50. doi: 10.1038/labinvest.2017.128. Epub 2017 Nov 20. Review.

34.

Functional analyses of a human vascular tumor FOS variant identify a novel degradation mechanism and a link to tumorigenesis.

van IJzendoorn DGP, Forghany Z, Liebelt F, Vertegaal AC, Jochemsen AG, Bovée JVMG, Szuhai K, Baker DA.

J Biol Chem. 2017 Dec 29;292(52):21282-21290. doi: 10.1074/jbc.C117.815845. Epub 2017 Nov 17.

35.

IWR-1, a tankyrase inhibitor, attenuates Wnt/β-catenin signaling in cancer stem-like cells and inhibits in vivo the growth of a subcutaneous human osteosarcoma xenograft.

Martins-Neves SR, Paiva-Oliveira DI, Fontes-Ribeiro C, Bovée JVMG, Cleton-Jansen AM, Gomes CMF.

Cancer Lett. 2018 Feb 1;414:1-15. doi: 10.1016/j.canlet.2017.11.004. Epub 2017 Nov 8.

PMID:
29126913
36.

Genetic polymorphisms in angiogenesis-related genes are associated with worse progression-free survival of patients with advanced gastrointestinal stromal tumours treated with imatinib.

Verboom MC, Kloth JSL, Swen JJ, van der Straaten T, Bovée JVMG, Sleijfer S, Reyners AKL, Mathijssen RHJ, Guchelaar HJ, Steeghs N, Gelderblom H.

Eur J Cancer. 2017 Nov;86:226-232. doi: 10.1016/j.ejca.2017.09.025. Epub 2017 Oct 18.

PMID:
29054076
37.

NAD Synthesis Pathway Interference Is a Viable Therapeutic Strategy for Chondrosarcoma.

Peterse EFP, van den Akker BEWM, Niessen B, Oosting J, Suijker J, de Jong Y, Danen EHJ, Cleton-Jansen AM, Bovée JVMG.

Mol Cancer Res. 2017 Dec;15(12):1714-1721. doi: 10.1158/1541-7786.MCR-17-0293. Epub 2017 Aug 31.

38.

Increased Risk of Breast Cancer at a Young Age in Women with Fibrous Dysplasia.

Majoor BC, Boyce AM, Bovée JV, Smit VT, Collins MT, Cleton-Jansen AM, Dekkers OM, Hamdy NA, Dijkstra PS, Appelman-Dijkstra NM.

J Bone Miner Res. 2018 Jan;33(1):84-90. doi: 10.1002/jbmr.3286. Epub 2017 Sep 20.

39.

Molecular Pathology of Bone Tumors: What Have We Learned and How Does It Affect Daily Practice?

Bovée JVMG.

Surg Pathol Clin. 2017 Sep;10(3):xiii-xiv. doi: 10.1016/j.path.2017.06.001. No abstract available.

PMID:
28797513
40.

Vascular Tumors of Bone: The Evolvement of a Classification Based on Molecular Developments.

van IJzendoorn DGP, Bovée JVMG.

Surg Pathol Clin. 2017 Sep;10(3):621-635. doi: 10.1016/j.path.2017.04.003. Review.

PMID:
28797505
41.

Integrating Morphology and Genetics in the Diagnosis of Cartilage Tumors.

de Andrea CE, San-Julian M, Bovée JVMG.

Surg Pathol Clin. 2017 Sep;10(3):537-552. doi: 10.1016/j.path.2017.04.005. Review.

PMID:
28797501
42.

Higher incidence rates than previously known in tenosynovial giant cell tumors.

Mastboom MJL, Verspoor FGM, Verschoor AJ, Uittenbogaard D, Nemeth B, Mastboom WJB, Bovée JVMG, Dijkstra PDS, Schreuder HWB, Gelderblom H, Van de Sande MAJ; TGCT study group.

Acta Orthop. 2017 Dec;88(6):688-694. doi: 10.1080/17453674.2017.1361126. Epub 2017 Aug 8.

43.

USP6 activation in nodular fasciitis by promoter-swapping gene fusions.

Patel NR, Chrisinger JSA, Demicco EG, Sarabia SF, Reuther J, Kumar E, Oliveira AM, Billings SD, Bovée JVMG, Roy A, Lazar AJ, Lopez-Terrada DH, Wang WL.

Mod Pathol. 2017 Nov;30(11):1577-1588. doi: 10.1038/modpathol.2017.78. Epub 2017 Jul 28.

44.

High-Throughput Screening of Myxoid Liposarcoma Cell Lines: Survivin Is Essential for Tumor Growth.

de Graaff MA, Malu S, Guardiola I, Kruisselbrink AB, de Jong Y, Corver WE, Gelderblom H, Hwu P, Nielsen TO, Lazar AJ, Somaiah N, Bovée JVMG.

Transl Oncol. 2017 Aug;10(4):546-554. doi: 10.1016/j.tranon.2017.05.007. Epub 2017 Jun 24.

45.

Serum levels of IGF-1 and IGF-BP3 are associated with event-free survival in adult Ewing sarcoma patients treated with chemotherapy.

de Groot S, Gelderblom H, Fiocco M, Bovée JV, van der Hoeven JJ, Pijl H, Kroep JR.

Onco Targets Ther. 2017 Jun 13;10:2963-2970. doi: 10.2147/OTT.S123726. eCollection 2017.

46.

Soft tissue angiofibroma: Clinicopathologic, immunohistochemical and molecular analysis of 14 cases.

Bekers EM, Groenen PJTA, Verdijk MAJ, Raaijmakers-van Geloof WL, Roepman P, Vink R, Gilhuijs NDB, van Gorp JM, Bovée JVMG, Creytens DH, Flanagan AM, Suurmeijer AJH, Mentzel T, Arbajian E, Flucke U.

Genes Chromosomes Cancer. 2017 Oct;56(10):750-757. doi: 10.1002/gcc.22478. Epub 2017 Jul 25.

PMID:
28639284
47.

Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients with IDH1-mutated or IDH2-mutated solid tumours.

Molenaar RJ, Coelen RJS, Khurshed M, Roos E, Caan MWA, van Linde ME, Kouwenhoven M, Bramer JAM, Bovée JVMG, Mathôt RA, Klümpen HJ, van Laarhoven HWM, van Noorden CJF, Vandertop WP, Gelderblom H, van Gulik TM, Wilmink JW.

BMJ Open. 2017 Jun 10;7(6):e014961. doi: 10.1136/bmjopen-2016-014961.

48.

IDH1 or -2 mutations do not predict outcome and do not cause loss of 5-hydroxymethylcytosine or altered histone modifications in central chondrosarcomas.

Cleven AHG, Suijker J, Agrogiannis G, Briaire-de Bruijn IH, Frizzell N, Hoekstra AS, Wijers-Koster PM, Cleton-Jansen AM, Bovée JVMG.

Clin Sarcoma Res. 2017 May 4;7:8. doi: 10.1186/s13569-017-0074-6. eCollection 2017.

49.

Update on hypoxia-inducible factors and hydroxylases in oxygen regulatory pathways: from physiology to therapeutics.

Ratcliffe P, Koivunen P, Myllyharju J, Ragoussis J, Bovée JV, Batinic-Haberle I, Vinatier C, Trichet V, Robriquet F, Oliver L, Gardie B.

Hypoxia (Auckl). 2017 Mar 15;5:11-20. doi: 10.2147/HP.S127042. eCollection 2017. Review.

50.

Loss of maternal chromosome 11 is a signature event in SDHAF2, SDHD, and VHL-related paragangliomas, but less significant in SDHB-related paragangliomas.

Hoekstra AS, Hensen EF, Jordanova ES, Korpershoek E, van der Horst-Schrivers AN, Cornelisse C, Corssmit EP, Hes FJ, Jansen JC, Kunst HP, Timmers HJ, Bateman A, Eccles D, Bovée JV, Devilee P, Bayley JP.

Oncotarget. 2017 Feb 28;8(9):14525-14536. doi: 10.18632/oncotarget.14649.

Supplemental Content

Loading ...
Support Center